Dr Lu discusses whether ESR1 mutation confirmation is required to consider therapy with oral selective estrogen receptor degraders. Ryan Haumschild, PharmD, MS, MBA: Calling out the treatment pathways ...

Efficacy assessment of a novel pan-RAS inhibitor in KRAS-mutant and wild type colorectal 3D bioprinted organoid tumor tissue. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...

Researchers led by teams at NYU Langone Health and its Perlmutter Cancer Center have reported on the development of antibodies that can selectively target cancer-related mutations in the extracellular ...

Molecular model of the tumor suppressor protein p53 (beige) bound to a molecule of DNA (red and blue). P53 maintains genomic stability by controlling cell division, repairing DNA damage, and ...